Surgery is the only potentially curative option for patients with pancreatic ductal adenocarcinoma (PDAC), but metastatic relapse remains common. We hypothesized that the expression levels of inflammatory cytokines could predict recurrence of PDAC, thus allowing to select patients who most likely could benefit from surgical resection.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, with the lowest 5-y relative survival rate among solid tumors at 7%, 1 and is projected to become the second leading cause of cancer-related death by 2030. 2 Surgery is the only potentially curative option for PDAC patients, but metastatic relapse remains common and no more than 20% of patients undergoing surgery and post-surgical therapy achieve long-term survival. 3 Thus, the identification of biologic markers able to predict metastatic recurrence of PDAC remains critical to select patients most likely to benefit from surgical resection. 4 Tumor microenvironment contains both innate and adaptive immune cells that communicate with each other by means of cytokines and chemokines production to control tumor growth and spread. 5 In this "immune contexture," the cytokine expression profile may be more relevant than its specific immune cell content, and provide malignant cells with continuous supply of growth and survival signals. [6] [7] [8] In PDAC, a dysfunctional immune system aids rather than controls cancer development and progression. 9 However, it is still unclear which cytokines or chemokines are critical for metastasis and prognosis of established tumors. 10 Previous studies examined the association between serum levels of several proinflammatory cytokines and overall survival (OS) in cohorts of patients with mostly advanced PDAC. In these studies, only a high level of IL6 was consistently demonstrated as an independent prognostic factor for poor OS. [11] [12] [13] [14] However, comprehensive cytokine profiles have not been performed in early PDAC to date, therefore it is still unclear the potential value of cytokines or chemokines in predicting recurrence in this disease.
Here, we investigated whether the preoperative expression levels of 23 cytokines in a large and prospective cohort of patients with resectable PDAC could be predictive of their Disease free survival (DFS) or OS, thus, serving as potential biomarker to select patients more likely to benefit from an upfront surgical resection.
Results

Association of patients' characteristics with OS and DFS
Two-hundred-eighty-seven patients admitted at the Unit of General and Pancreatic Surgery of the Azienda Ospedaliera Universitaria Integrata of Verona between 2012 and 2014 with suspected PDAC were assessed for eligibility. Among them, a total of 90 treatment-na€ ıve resectable patients with histologically proven non-metastatic PDAC were included in the study (Fig. 1) . Patients' characteristics are shown in Table 1 . The mean age was 63 y and 51% were male. Most of them had tumors in the head of pancreas (79%), T3 stage (96%), and positive nodes (86%). Radical resection (R0) was obtained in 46% of cases. The majority of patients received adjuvant chemotherapy (82%), mostly with a gemcitabine-based regimen (97%). After a median followup of 26.9 mo, the median DFS was 19.9 mo and the median OS was not reached (data not show). Compliance with REMARK guidelines is reported in Table S1 
Association of circulating cytokines and chemokines levels with OS and DFS
To determine whether patterns of circulating cytokines and chemokines could predict patients outcome, we measured the concentration of a panel of 23 different T H 1, T H 2, T H 9, T H 17 cytokines, chemokines, and growth factors in preoperative plasma samples from 90 treatment na€ ıve patients with nonmetastatic PDAC ( Table 2 ). The optimal cutoff thresholds able to significantly predict patients' outcome were evaluated for each cytokine (Table 2 and Fig. 2A and B) .
Concentration of the T H 2 cytokines IL4, IL5, IL6 of the monocyte/macrophage infiltration cytokines MIP1a, GM-CSF, and MCP-1, and of IL17a, IP10, and IL1b at level higher than cutoff were significantly associated with a shorter patient's median OS.
Concentration of IL4 and IP10 higher than cutoff were significantly associated with shorter median DFS. ON the contrary, concentration of T H 1 cytokines TNFa and interferon (IFN)g and of IL9 and IL1Ra higher than cutoff were significantly associated with an increased median DFS. A summary of the overall findings of the study is reported in Fig. 3B .
An additional analysis demonstrated that patients whose DFS exceeded 8 mo had significantly less circulating IL4 level than did patients with DFS<8 mo (p D 0.016) (Fig. 2C) . The optimal cutoff threshold of 9.365 pg/mL had a sensitivity of (Table 3) . Since the multivariate analysis revealed both IL4 and TNFa as independent predictors of DFS, we tried to determine whether the two factors could interact to affect the prognosis of patients. Indeed, concurrent plasma concentrations of IL4 and TNFa lower and higher than their respective cutoffs, identified patients with best prognosis (HR D 0.313, p < 0.0001) (Fig. 3A) .
Discussion
To our knowledge, this study represents the most comprehensive profiling of cytokines in the largest prospective cohort of resectable PDAC patients to date. We demonstrated that IL4 is the most significant independent prognostic factor for DFS in resectable PDAC patients among a series of cytokines, representing a potential biomarker to stratify patients suited for surgery from patients with high risk of early recurrence who may avoid unnecessary resections.
T H 2 immune response is defined by the cytokines IL4, IL5, IL9, and IL13, which induce in turn a complex inflammatory response characterized by T H 2 subset of CD4 C helper T cells, eosinophils, mast cells, basophils, and alternatively activated macrophages. In particular, IL4 is the signature cytokine of the T H 2 effector cells, by acting as both an inducer and an effector cytokine of these cells. 15 In most solid tumors, it is generally conceived that a T H 2 inflammation promotes tumorigenesis and tumor growth. In particular, several studies provided evidence for a general T H 2 shift in PDAC with a predominance of T H 2 cytokines in the plasma of patients (reviewed in 16 ). Important studies mainly by the group of Protti and colleagues 17 provided evidence on the mechanisms underlying these observations. They identified a cross talk between PDAC cells and microenvironment components, resulting in thymic stromal lymphopoietin production by activated cancer-associated fibroblasts that, in turn, induced a T H 2 cell polarization through myeloid dendritic cell conditioning. The T H 2 (GATA-3 C )/T H 1 (T-bet C ) lymphoid cells ratio was independently predictive of DFS and OS in a population of resected PDAC patients. More recently, they demonstrated that basophils recruited in tumor-draining lymph nodes of PDAC patients regulate tumor promoting T H 2 inflammation, being the early source of IL4 necessary for the full stabilization of the T H 2 phenotype. 18 Our study contributes to this field by providing evidence, through an inductive approach, for a T H 2 shift in those PDAC patients for which we expect an early recurrence of disease. We examined a comprehensive immune circulating biomarkers panel demonstrating that high pre-surgical plasma levels of the T H 2 cytokines IL4, IL5, IL6, and low plasma levels of T H 1 cytokines TNFa and INFg were significantly associated with worst patients' outcome. More importantly, in the multivariate analysis, we confirmed IL4 as the strongest independent prognostic factor for DFS, a clinical end point directly correlated with tumor aggressiveness that could be not corrupted by the effect of subsequent lines of therapy. IL4 was identified as the original inducer of the polarization of the alternatively activated M2 macrophages, 19 which are generally conceived to suppress antitumor immunity and to favor growth and spreading in solid tumors. 20 However, recent studies correlating the infiltration of M2-polarized CD163 C macrophages and prognosis in patients affected by resectable PDAC reached opposite conclusions. 21, 22 In this regard, our study demonstrated that high plasma levels of the cytokines involved in macrophage recruitment MIP1a, GM-CSF, and MCP1 were significantly associated with shorter patients' survival after surgery.
Beside T H 2 inflammatory cells, a FOXP3 C regulatory T cells (T reg ) enriched pancreatic tumor infiltrate has been found to correlate with shorter patient survival. 23, 24 This cell subtype can be recruited in the tumor microenvironment by the chemokine IP10 expressed by pancreatic stellate cells, leading to immunosuppressive and tumor-promoting effects. 25, 26 Consistently with these observations, we demonstrated that high IP10 plasma level were negatively associated with patients' OS.
In conclusion, our present study prospectively demonstrated through an inductive approach that circulating markers of a T H 2 immune response, and macrophages and T reg recruitment could be predictive of early metastatic relapse and poor prognosis in resectable PDAC patients. The simple measurement of these cytokines by a non-invasive, blood-based assay, and the interpretation of their significance based on the cutoff thresholds here determined could represent a significant advantage over the assessment of the immune cells infiltration and differentiation in preoperative tumor biopsies, which often provide insufficient material to generate intratumor immune profiles and could not completely recapitulate the heterogeneity of these tumors. IL4 emerged among several other cytokines as the most significant independent prognostic factor for DFS in resectable PDAC patients. The expression of this T H 2 cytokine could be useful to select patients with high risk of early recurrence who may avoid an unnecessary resection.
Patients and methods
Patients
Inclusion criteria for this study were histopathological confirmation of PDAC, no prior neo-adjuvant therapy, no evidence of metastatic disease, eligible for surgical resection. Peripheral blood samples were prospectively collected from all patients before surgical resection using EDTA-containing tubes. Plasma was isolated from each sample by centrifugation and stored at ¡20 C. The variables evaluated included age, gender, tumor location, tumor size, differentiation status, lymph node involvement and TNM stage, 27 patterns of resection margins, patterns of recurrence. DFS was determined from the time of surgery until local or metastatic PDAC tumor recurrence. OS was defined as the time of surgery to death. Informed consent was obtained from all subjects. This study was performed in accordance with the ethical standards of the Helsinki Declaration of the World Medical Association.
Multiplex cytokines profiling
Using a 23-plex kit from Bio-Rad, all plasma specimens were analyzed for interleukin (IL)1b, IL2, IL4, IL5, IL6, IL7, IL8 (CXCL8), IL9, IL-12p70, IL13, IL15, IL17a, eotaxin (CCL ¡ 11), IL1Ra, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IFNg, IP10 (CXCL10), monocyte chemoattractant protein (MCP1; CCL2), macrophage inflammatory protein 1a (MIP1a; CCL3), MIP1b (CCL4), TNFa, and vascular endothelial growth factor (VEGF). All Luminex assays were performed according to the instructions provided by the manufacturer (Bio-Rad Laboratories). All Luminex assays were performed according to the instructions provided by the manufacturer (Bio-Rad Laboratories). Median fluorescence intensities were collected on a Luminex-200 instrument, using Bio-Plex Manager software version 6.2. Standard curves for each cytokine were generated using the premixed lyophilized standards provided in the kits.
Cytokine concentrations in samples were determined from the standard curve using a 5-point regression to transform mean fluorescence intensities into concentrations.
Statistical analysis
Survival curves were drawn by Kaplan-Meier estimates and compared by log rank test. Univariate and multivariate analyses of DFS and OS, with stepwise variable selection, were conducted by Cox's proportional hazard regression models. Multivariate analysis was conducted using the clinical-pathologic variables with a p-value < 0.05 and the strongest significant molecular variables in univariate analysis (p-value < 0.01). The optimal cutoff thresholds for soluble biomarkers were obtained based on the maximization of the Youden's statistics J D sensitivityCspecificityC1 28 using an R-based software as described in Budczies et al. 29 Statistical analyses were performed using SPSS 24.0 statistical software (SPSS, Inc.), GraphPad Prism software program (version 6.0; GraphPad Software), and the statistical language R.
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